Featured Research

from universities, journals, and other organizations

Homing in on cancer with new imaging method

Date:
March 3, 2014
Source:
University of Zurich
Summary:
There are many reasons why in the era of cutting-edge medicine it is still difficult to cure cancer. A tumor may, for instance, consist of different tumor cell subpopulations, each of which has its own profile and responds differently to therapy – or not. Furthermore, the cancer cells and the healthy cells in the body interact and communicate with one another. How a tumor then actually develops and whether metastases form depends on which signals a tumor cell receives from its environment. With the development of a new method a team of reserachers has succeeded in comprehensively profiling and visualizing tumor cells from patient samples.

Cancer is the second most common cause of death in Switzerland. There are many reasons why in the era of cutting-edge medicine it is still difficult to cure this disease. A tumor may, for instance, consist of different tumor cell subpopulations, each of which has its own profile and responds differently to therapy -- or not. Furthermore, the cancer cells and the healthy cells in the body interact and communicate with one another. How a tumor then actually develops and whether metastases form depends on which signals a tumor cell receives from its environment.

With the development of a new method the team around Prof. Bernd Bodenmiller from the Institute of Molecular Life Sciences at the University of Zurich -- in cooperation with ETH Zurich and University Hospital Zurich -- has succeeded in comprehensively profiling and visualizing tumor cells from patient samples. This promising method has now been published in Nature Methods.

New imaging method -- major opportunity

Setting out to determine a tumor's cell profile, its neighborhood relationships and the circuit structure within and in between cells is a highly complex endeavour. This is because the biomarkers, i.e. the specific molecules of the various cell types and their circuits, have to be measured in their spatial relationships. "With our method it is possible to obtain a comprehensive picture using a novel imaging technique that currently can simultaneously record 32, and in the near future more than one hundred biomarkers," explains Bernd Bodenmiller, the study coordinator. Furthermore, thanks to state-of-the-art imaging the information about the cells' neighborhood relationships is kept and their direct impact on the cellular switch and control circuits can be visualized.

The new technique is based on methods which are already routinely used in hospitals -- with two important innovations. First, the biomarkers are visualized using pure metal isotopes instead of dyes. To do so, biomarkers on very thin tissue sections are labelled with antibodies. The antibodies are coupled to the pure metal isotopes. Then tiny pieces of tissue are removed with a laser system developed by Prof. Detlef Günther from the ETH Zurich, and the metal isotopes of the pieces are measured with a mass spectrometer which can determine the mass and quantity of the individual metal isotopes. "This trick gets round the problem of the limited number of colours in the analysis of biological samples," comments Bodenmiller.

Secondly, information about the cells, and their control circuits, is no longer qualitative. With the new measurement method it is possible to precisely determine which cells experience what effect and to which extent. In this way the weak points of the control system can be pinpointed and this helps in the development of new therapeutic approaches. This is the reason, so Bodenmiller, why it is becoming increasingly important to understand these interactions for diagnosis and therapy.

Customized treatment is the goal

The initial measurement results of the new biomarker technique for breast cancer have revealed the heterogeneity of tumors. As a consequence of major growth, some tumors suffer from oxygen deficiency on the inside, other misuse the body's own immune cells to drive their growth. Cell-cell interaction and cell location in the centre or on the edges of the tumor also have a decisive influence. One thing is clear: no tumor is like any other and Bodenmiller believes that treatment should reflect this. In a next step his research team wishes to use the new measurement method to explore the roles played by control circuits and cell communication in metastasis formation.


Story Source:

The above story is based on materials provided by University of Zurich. Note: Materials may be edited for content and length.


Journal Reference:

  1. Charlotte Giesen, Hao A O Wang, Denis Schapiro, Nevena Zivanovic, Andrea Jacobs, Bodo Hattendorf, Peter J Schüffler, Daniel Grolimund, Joachim M Buhmann, Simone Brandt, Zsuzsanna Varga, Peter J Wild, Detlef Günther, Bernd Bodenmiller. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nature Methods, 2014; DOI: 10.1038/nmeth.2869

Cite This Page:

University of Zurich. "Homing in on cancer with new imaging method." ScienceDaily. ScienceDaily, 3 March 2014. <www.sciencedaily.com/releases/2014/03/140303083555.htm>.
University of Zurich. (2014, March 3). Homing in on cancer with new imaging method. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/03/140303083555.htm
University of Zurich. "Homing in on cancer with new imaging method." ScienceDaily. www.sciencedaily.com/releases/2014/03/140303083555.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) — Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) — Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins